CRSP

CRISPR Therapeutics has transitioned to a commercial biotech with its approved gene-editing therapy Casgevy for blood disorders. The company has several promising pipeline candidates including CTX310 for cholesterol/triglycerides, zugo-cel for autoimmune diseases and blood cancers, and CTX611 as an anticoagulant. While significant clinical and commercial progress could drive substantial stock gains by 2030, investors face considerable risks including potential clinical trial failures and uncertain profitability economics for one-time gene-editing treatments.

Cathie Wood's ARK Invest purchased $3.4 million worth of CRISPR Therapeutics stock on consecutive trading days (Oct. 9 and Oct. 12), bringing her total holdings to $379.1 million. The investment reflects confidence in CRISPR's approved therapy Casgevy and promising pipeline candidates CTX-310 and CTX611, despite the stock declining 25% over the past year. CRISPR reported strong Q2 revenue growth of 151% year-over-year and maintains $2.36 billion in cash.

CRISPR Therapeutics AG stock fell 4.48% on October 16, 2026, significantly underperforming the S&P 500's 1.09% decline. The stock has depreciated 10.13% over the past month, lagging the Medical sector's 2.68% gain. While analysts expect strong revenue growth of 1017.42% year-over-year for the upcoming quarter, the company maintains a Zacks Rank of #3 (Hold) with a slight 0.22% downward revision to consensus EPS estimates.